AP NEWS

Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H2 2018 Featuring AbbVie, Pfizer, Novartis, GSK, Amgen, and More - ResearchAndMarkets.com

September 28, 2018

DUBLIN--(BUSINESS WIRE)--Sep 28, 2018--The “Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Atopic Eczema) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 42, 20, 1, 46, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 4 and 2 molecules, respectively.

Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Companies Featured

AbbVie Inc Allergan Plc Almirall SA Amgen Inc Bioleaders Corp Blueberry Therapeutics Ltd Celgene Corp DURECT Corp Eli Lilly and Co Evotec AG F. Hoffmann-La Roche Ltd GlaxoSmithKline Plc Golden Biotechnology Corp Han Wha Pharma Co Ltd Heptares Therapeutics Ltd iCo Therapeutics Inc Immune Pharmaceuticals Inc Incyte Corp Inflamalps SA Kyowa Hakko Kirin Co Ltd Lead Pharma Holding BV LEO Pharma A/S Madam Therapeutics BV Novan Inc Novartis AG Orbis Biosciences Inc Otsuka Holdings Co Ltd Pfizer Inc Pharmedartis GmbH Spherium Biomed SL sterna biologicals Gmbh & Co KG TaiwanJ Pharmaceuticals Co Ltd The Geneva Biotech Center SA Torrent Pharmaceuticals Ltd and many more...

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/79ppfz/atopic_dermatitis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180928005370/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Dermatological Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/28/2018 11:02 AM/DISC: 09/28/2018 11:01 AM

http://www.businesswire.com/news/home/20180928005370/en

AP RADIO
Update hourly